Minimizing insulin injection pain remains a significant challenge in modern medicine. Choosing the right needle significantly impacts patient experience and outcomes. High-quality needles, like WellFine 34G, offer several key advantages:
Injection pain depends on four main factors:
For minimal pain, select the highest-quality, shortest, and thinnest needle appropriate for your needs. While 32G (0.23mm) x 4mm needles are popular, the 34G (0.18mm) needle represents a significant advancement. Its 40% smaller puncture area translates to less trauma and pain.
However, reducing needle diameter presents challenges. Decreasing the outer diameter necessitates reducing the inner diameter, which increases insulin flow resistance, especially with thicker or microcrystalline solutions.
WellFine 34G needles utilize Thin Wall (TW) technology to address this. This maintains the inner diameter (approximately 0.09mm) similar to a 32G needle, while significantly reducing the outer diameter. This innovative approach ensures smooth insulin delivery without compromising needle strength or sharpness.
The demanding specifications of 34G needles require advanced materials and manufacturing processes. Major manufacturers like Becton Dickinson and Novo Nordisk do not currently produce 34G insulin needles. While Terumo's Nanopass 34G needles exist, they lack Russian registration and are expensive.
WellFine 34G (4mm and 5mm) needles, manufactured by MedExel (a South Korean company with a history of collaboration with German and US partners), are now officially available in Russia with all necessary approvals. These needles, made with cutting-edge Japanese steel, offer a unique solution for patients of all ages, especially those with low pain tolerance or a history of injection site complications.
WellFine 34G needles represent a significant technological advancement in the Russian insulin needle market, offering a superior solution for improved diabetes management and enhanced quality of life.





